XNASXCUR
Market cap44mUSD
Dec 24, Last price
17.00USD
1D
-13.00%
1Q
364.48%
IPO
-97.17%
Name
Exicure Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
42.31%
Rev. gr., 5y
24.29%
Revenues
0k
-100.00%
Net income
-17m
L+555.07%
CFO
-10m
L-70.95%
Earnings
Jun 16, 2025
Profile
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 28,826 -6,068.12% | (483) -102.91% | |||||||
Cost of revenue | 14,996 | 32,513 | 63,845 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (14,996) | (3,687) | (64,328) | ||||||
NOPBT Margin | 13,318.43% | ||||||||
Operating Taxes | 209 | 1,680 | |||||||
Tax Rate | |||||||||
NOPAT | (14,996) | (3,896) | (66,008) | ||||||
Net income | (16,914) 555.07% | (2,582) -95.97% | (64,102) 159.86% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,440 | 4,901 | 11,464 | ||||||
BB yield | -23.40% | -18.45% | -12.80% | ||||||
| Debt | |||||||||
Debt current | 626 | 539 | 7,332 | ||||||
Long-term debt | 12,078 | 14,073 | 15,267 | ||||||
Deferred revenue | 11,509 | ||||||||
Other long-term liabilities | 656 | ||||||||
Net debt | 11,888 | 4,835 | (25,742) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (10,357) | (35,658) | (34,819) | ||||||
CAPEX | (10) | (968) | |||||||
Cash from investing activities | (1,078) | 4,696 | 43,085 | ||||||
Cash from financing activities | 3,674 | (3,105) | 1,116 | ||||||
FCF | (11,406) | (2,180) | (65,156) | ||||||
| Balance | |||||||||
Cash | 816 | 8,577 | 39,141 | ||||||
Long term investments | 1,200 | 9,200 | |||||||
Excess cash | 816 | 8,336 | 48,365 | ||||||
Stockholders' equity | (189,562) | (172,649) | (170,058) | ||||||
Invested Capital | 199,258 | 194,877 | 208,191 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 8,014 | 4,619 | 2,954 | ||||||
Price | 2.90 -49.54% | 5.75 -81.03% | 30.32 -88.58% | ||||||
Market cap | 23,252 -12.46% | 26,562 -70.34% | 89,548 -88.40% | ||||||
EV | 35,140 | 31,397 | 63,806 | ||||||
EBITDA | (13,621) | (1,831) | (62,549) | ||||||
EV/EBITDA | |||||||||
Interest | 595 | 1,691 | |||||||
Interest/NOPBT | |||||||||